Sales Head - Pharma Liquids & Solids

Syntegon reports 7% sales growth, record order backlog in H1 2026. September 8, 2026 Syntegon reported first-half 2026 group sales of Euro 883 million, up 7% year-on-year, with adjusted EBITDA rising 16% to Euro 148 million. The adjusted EBITDA margin expanded to 16.8%, up 130 basis points versus the first half of 2025. Order intake reached Euro 964 million, with a book-to-bill ratio of 1.09 and a record order backlog of Euro 1.3 billion. "Our first-half 2026 results underline the positive impact of our strategy and the strength of Syntegon's market position," said Torsten Türling, chief executive officer of Syntegon. "Our Pharma business remains our strongest growth engine. We achieved major new customer wins and market share gains in the expanding biologics market globally and in the United States in particular." "Our first-half results demonstrate Syntegon's strong operating leverage. Adjusted EBITDA increased more than twice as fast as sales, taking the margin to 16.8%," added Eros Carletti, chief financial officer of Syntegon. "This reflects the stronger earnings contribution from Pharma, operational discipline and continued improvements in project execution. Our solid order book provides a strong foundation for continued profitable growth and cash generation." Pharma business achieves double-digit sales growth According to the company, the pharmaceutical and biotech industries continue to benefit from structural growth drivers, including the expansion of biologics and injectable medicines and growing demand for more flexible and highly automated pharmaceutical production. Syntegon's Pharma sales increased by 14% in the first half of 2026, making the business the strongest contributor to Group growth. Demand remained strong for aseptic Fill & Finish and isolator-equipped line solutions, supported by continued investment in biologics and injectable medicines as well as increasingly stringent regulatory requirements. Pharma Solid also delivered double-digit growth, driven by strong demand for capsule-filling solutions and an expanded granulation product portfolio. The company said the Pharma performance reflects its customer-centric approach under its lifecycle partner strategy, with new solutions contributing to significant new customer wins. In the Pharma and Biotech industry, Europe remained a resilient core market. In Asia, Pharma sales rose substantially year-on-year, with the company citing further market share gains in the expanding biologics market and benefits from its operations in China. In the United States, Pharma order intake increased significantly, which the company attributed to its focused growth strategy for the region. Food business growth muted by challenging market dynamics Market dynamics remained challenging in the first half of 2026, particularly in the Chocolate & Bars industry, where Syntegon holds the position of global market leader according to the company. Customers continued to face cost pressure, leading to cautious investment decisions. Against this backdrop, Syntegon launched new product solutions aimed at supporting customers' need for higher efficiency and flexibility in the first half. The company said the value of these solutions is reflected in customers' increasing adoption of the SVX platform, a vertical packaging solution. In response to the more challenging market dynamics, the company stated it is taking measures to address the market challenges and defend its margin position. Innovation addresses the needs of the 'Factory of the Future' The company said customers increasingly seek more automated, flexible and efficient production as they respond to labor shortages, cost pressure, stricter regulations and growing portfolio complexity. In the first half, Syntegon launched next-generation solutions with enhanced automation, robotics and AI-enabled functionality, which the company said support customers in developing their 'Factory of the Future'. Combined with Syntegon's lifecycle services, the company said customers achieve the lowest total cost of ownership across their operational footprint. Syntegon confirms full-year 2026 outlook of growth and margin expansion For the full year 2026, Syntegon confirmed its outlook. Citing a healthy order book, sustained market demand in Pharma and Biotech, and a continued focus on disciplined execution, the company said it expects further profitable growth in 2026.

Syntegon opens new OSD Customer Center in Fellbach. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Advertisement - * State-of-the-art customer center for the pharmaceutical and nutraceutical industries * Customer focus, innovation, and growth under one roof * Close collaboration between customer center and production for even faster time-to-market of new drugs and nutraceuticals Stuttgart (Germany), September 1, 2026. Syntegon, a strategic lifecycle partner to the pharmaceutical, biotech, and food industries, has opened its new OSD Customer Center in Fellbach following the move from Waiblingen. Cleanrooms, a powder laboratory, and state-of-the-art equipment create ideal conditions for pharmaceutical and nutraceutical trials involving solid oral dosage forms (OSD) such as capsules and tablets. From lab to production, customers benefit from extensive knowledge transfer, helping accelerate the time-to-market of new pharmaceuticals and dietary supplements. Customer and employee focus as a driving force. "With a double-digit million investment in Fellbach, we are sending a strong signal in support of our growth strategy and creating an environment that aims to always be one step ahead," says Thomas Hartkämper, Executive Vice President Pharma Solid at Syntegon. "The OSD Customer Center supports our customers and employees in taking formulation and manufacturing processes to a new level." Spanning 7,900 square meters, the customer center and production facilities have moved even closer together. "Short distances, digital processes, and a future-proof infrastructure create the framework for genuine collaboration on an equal footing," says site manager Markus Reitz. Within the first few months after the move from Waiblingen, delivery reliability has already increased by 10 percent thanks to improved cross-departmental collaboration, agile work methods, and greater efficiency. From development to production. The OSD Customer Center offers pharmaceutical and nutraceutical developers and manufacturers an ideal location to test future formulations or existing products on production equipment. Capsule fillers and sealers as well as tablet presses are available for this purpose in Fellbach. "As a true lifecycle partner, we support our customers from the initial idea through to series production," says Reitz. The successful OSD Academy will also be held in Fellbach, in addition to Schopfheim. While the event in Schopfheim on October 20-22 will focus on coating, the first session in Fellbach is scheduled for next year. Syntegon is a leading global technology company and strategic life cycle partner to the pharmaceutical, biotech, and food industries. With a strategic focus on the growing pharmaceutical and biotech sectors, the company plays a vital role in global healthcare, providing in-depth process expertise and mission-critical technologies for the safe, efficient, and compliant production of essential medicines. In the food sector, Syntegon is recognized for high-speed, high-precision packaging solutions, drawing on unique engineering excellence to help manufacturers improve performance and product quality. Its global service business supports more than 70,000 installed systems with a comprehensive lifecycle offering, ensuring uptime, efficiency, and long-term value. In fiscal year 2025, Syntegon generated 1.75 billion euros in sales. Headquartered in Stuttgart, Germany, the company employs 7,300 people at 49 locations in more than 20 countries. With over 160 years of industry expertis... Read more" Send Enquiry for this story. Never miss a pharmaceutical headline. The pharmaceutical industry moves fast - stay on top of it with its must - read briefings. * The top pharma and life sciences stories, straight to your inbox * The biggest news, features, interviews, and analysis * Dedicated coverage of the key developments driving the global pharmaceutical sector - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call

Syntegon expands pharma competence in Fellbach. The focus is on development and production processes for tablets and capsules - including the filling and sealing of capsules. 2nd September 2026 Picture: Syntegon Syntegon has opened a new customer centre for solid oral dosage forms at its Fellbach site. The focus is on development and production processes for tablets and capsules - including the filling and sealing of capsules. The company invested a double-digit million amount in the new location. The OSD Customer Center was established on an area of 7,900 square metres following its relocation from Waiblingen. It comprises cleanrooms, a powder laboratory and facilities for trials with oral solid dosage forms (OSD). Pharmaceutical and nutraceutical manufacturers can use it to test new formulations and production processes under real-world conditions. Focus on capsule filling and sealing. For the trials, capsule fillers and sealers, as well as tablet presses, are available in Fellbach, among other equipment. This enables manufacturers to test important processing steps for medicines and food supplements before the products go into series production. According to Syntegon, the spatial proximity in particular between the customer centre and production is intended to facilitate the transfer of knowledge. As a result, development and manufacturing processes could be transferred more quickly to subsequent production. The company also expects this to lead to shorter time-to-market periods for new medicines and dietary supplements. "With an investment in the tens of millions, we are sending a strong signal for our growth strategy in Fellbach and creating an environment designed to always be one step ahead." Thomas Hartkämper, Executive Vice President Pharma Solid at Syntegon Syntegon also points to efficiency gains from the move. In the very first months, delivery reliability had increased by ten percent through improved cross-departmental collaboration, agile working methods, and higher efficiency. OSD Academy also in Fellbach in future. The new centre is also to be used for training courses. The OSD Academy, previously held in Schopfheim among other places, will in future also take place in Fellbach. The first edition at the new location is planned for 2027.